Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice

Osteoporosis International

Volumn 24, Issue 4, 2013, Pages 1483-1489

  Weycker, D ^a   Lamerato, L ^b   Schooley, S ^b   Macarios, D ^c   Siu Woodworth, T ^a   Yurgin, N ^c   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c AMGEN INC   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Medication adherence; Osteopenia; Osteoporosis; Treatment effectiveness

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; BONE DENSITY; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HIP JOINT; HUMANS; MEDICATION ADHERENCE; MICHIGAN; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876489280     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2108-5     Document Type: Article

References (18)

1. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
2. McCarus DC (2006) Fracture prevention in postmenopausal osteoporosis: a review of treatment options. Obstet Gynecol Surv 61:39-50
3. Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291-1298
4. Cranney A, Guyatt G, Griffith L et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
5. Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077-2082
6. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
7. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
8. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
9. Weycker D, Macarios D, Edelsberg J, Oster G (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652
10. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
11. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
12. Ettinger B, Pressman AR, Schein J et al (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation. JMCP 4:488-492
13. Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with drug therapy and risk of fracture. Osteoporos Int 18:271-277
14. Adami S, Isaia G, Luisetto G et al (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565-1570
15. Feldstein AC, Weycker D, Nichols G et al (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
16. Yood RA, Emani S, Reed JI et al (2003) Adherence with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
17. Bell NH, Bilezikian JP, Bone HG et al (2002) Alendronate increase bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 87:2792-2797
18. Chesnut CH, McClung MR, Ensrud KE et al (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152